Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma

医学 危险系数 置信区间 单变量分析 比例危险模型 内科学 化疗 阶段(地层学) 放射治疗 多元分析 核医学 肿瘤科 外科 生物 古生物学
作者
Raj Singh,Hayden Ansinelli,Dana Sharma,Jan Jenkins,Joanne Davis,John A. Vargo,Sanjeev Sharma
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (7): 602-606 被引量:10
标识
DOI:10.1097/coc.0000000000000561
摘要

To utilize the RSSearch Patient Registry (RSSPR) to examine local control (LC), overall survival (OS), and toxicities following stereotactic body radiation therapy (SBRT) for stage I (T1-T2/N0) medically inoperable small cell lung carcinoma (SCLC).We searched the RSSPR for medically inoperable stage I SCLC patients treated with definitive SBRT. Potential predictive factors of OS were estimated using the Kaplan-Meier method as well as a Cox proportional hazards model.Twenty-one patients were identified with medically inoperable stage I SCLC that met inclusion criteria. Fourteen patients had stage IA SCLC (T1N0) and 7 patients had stage IB SCLC (T2N0) with a median gross tumor volume of 10.1 cm (range: 0.72 to 41.4 cm). The median number of fractions was 4 (range: 3 to 5), and the median BED10 was 105.6 Gy10 (range: 72 to 239.7 Gy10). Four patients received adjuvant chemotherapy. One- and 2-year actuarial OS rates were 73.1% (95% confidence interval [CI]: 36.8%-90.1%) and 36.6% (95% CI: 9.0%-65.7%), respectively. Factors found to be associated with 1-year OS on univariate analysis included T2 disease (85.5% vs. 33.3%; P=0.03), adjuvant chemotherapy (100% vs. 66.3%; P=0.11), and gross tumor volume ≥10 cm (100% vs. 52.5%; P=0.10). On multivariate analysis, adjuvant chemotherapy was associated with improved OS (hazard ratio=0.07 [95% CI: 0.13-0.37; P=0.002]). The 1-, 2-, and 3-year LC rates were 100%, and 1- and 2-year progression-free survival (PFS) rates were 85.7% (95% CI: 33.4-97.9%) and 42.9% (95% CI: 1.1-85.3%), respectively. Similar to OS, patients with T1N0 disease had superior PFS as compared to T2N0 disease (P=0.01). Toxicities were reported by 3/21 (14.3%) of patients with none ≥ grade 3 and no esophageal toxicities.SBRT was well-tolerated in the treatment of stage I SCLC with excellent LC achieved. Patients with T1N0 stage IA SCLC were noted to have improved PFS and OS following SBRT as compared with T2N0 Stage IB SCLC. Adjuvant chemotherapy was found to result in improved OS for stage I SCLC patients over SBRT alone.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
LL完成签到,获得积分10
刚刚
八月宁静发布了新的文献求助10
刚刚
刚刚
1秒前
波鲁鲁爱喝酸奶完成签到 ,获得积分10
1秒前
2秒前
核桃应助钱浩然采纳,获得10
4秒前
4秒前
脑洞疼应助张张张哈哈哈采纳,获得10
4秒前
5秒前
颠覆乾坤发布了新的文献求助10
6秒前
小王加油啊啊啊完成签到 ,获得积分10
6秒前
虚幻沛文完成签到 ,获得积分10
7秒前
hua完成签到 ,获得积分10
7秒前
zyf发布了新的文献求助10
8秒前
Ray完成签到,获得积分10
9秒前
yukiseto完成签到 ,获得积分10
9秒前
caozhi完成签到,获得积分10
9秒前
有魅力的发卡完成签到,获得积分10
10秒前
包容的若风完成签到,获得积分10
10秒前
szxnb666完成签到,获得积分20
11秒前
开心薯片完成签到,获得积分10
11秒前
HHH完成签到,获得积分10
12秒前
黑黑黑完成签到,获得积分10
13秒前
Kelly1426完成签到,获得积分10
14秒前
海边的曼彻斯特完成签到 ,获得积分10
14秒前
turbohero完成签到,获得积分10
14秒前
量子星尘发布了新的文献求助10
15秒前
英俊的铭应助开心薯片采纳,获得10
15秒前
16秒前
八月宁静完成签到,获得积分10
17秒前
小曾完成签到,获得积分10
17秒前
zyf完成签到,获得积分10
18秒前
高山流水完成签到,获得积分10
18秒前
咎淇完成签到,获得积分10
18秒前
kilig完成签到 ,获得积分10
19秒前
顾矜应助烊烊采纳,获得10
19秒前
平平无奇打工人完成签到 ,获得积分10
22秒前
Young完成签到 ,获得积分10
23秒前
陳某完成签到,获得积分10
24秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022